SCHEMBL5738151

SCHEMBL5738151

Clc1cn2c(n1)sc1ccc[c]c12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20893213 0.73 TNKS2 (0.50)
SCHEMBL2918338 0.72 IDO1 (0.33)
SCHEMBL16432341 0.66 SMN1; SMN2 (0.49)
SCHEMBL2057008 0.60 ALDH1A1 (0.40)
SCHEMBL1450408 0.58 L3MBTL1 (0.34)
SCHEMBL6244145 0.55 LOXL2 (0.31)
SCHEMBL8402940 0.54 TNKS2 (0.51)
SCHEMBL2928704 0.54 HCAR2 (0.53)
SCHEMBL20876092 0.54 TNKS2 (0.50)
SCHEMBL19521479 0.54 PSMB8 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1455779-B1 INDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH CORP (US) 2006-08-09 EP disclosed
US-7022701-B2 Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2006-04-04 US disclosed
US-6770642-B2 FOR USE IN TREATMENT OF CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, EPILEPSY, OBSESSIVE COMPULSIVE DISORDER, ATTENTION DEFICIT DISORDER, MIGRAINE, COGNITIVE MEMORY ENHANCEMENT, ALZHEIMER'S DISEASE WYETH 2004-08-03 US disclosed